Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,746.50
Bid: 1,700.00
Ask: 1,800.00
Change: 0.00 (0.00%)
Spread: 100.00 (5.882%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,746.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Signs Ebola may be levelling off in Sierra Leone - WHO

Wed, 07th Jan 2015 22:15

* Sierra Leone still records 248 new cases in past week

* More than 8,000 killed worldwide in epidemic to date

* WHO to host meeting on experimental vaccines on Thursday (Adds quotes from UN and WHO officials in Liberia)

By Stephanie Nebehay and James Harding Giahyue

GENEVA/MONROVIA, Jan 7 (Reuters) - Sierra Leone, the countryworst affected by Ebola, reported nearly 250 new confirmed casesin the past week but the spread of the virus there may beslowing, the World Health Organization said on Wednesday.

The epidemic has taken 8,235 lives out of 20,747 known cases worldwide over the past year, it said. Overall, 838 healthworkers have been infected, killing 495 of them.

The WHO's weekly report was based on figures reported byauthorities in nine countries. Guinea, Liberia and Sierra Leoneaccount for the majority of infections and fatalities.

"There are signs that case incidence may have levelled offin Sierra Leone, although with 248 new confirmed cases reportedin the week to 4 January 2015, it remains by far theworst-affected country at present," the WHO said.

Cases are still under-reported and unevenly spread in WestAfrica. The virus is spreading most rapidly in western SierraLeone, where the capital Freetown reported 93 of the newconfirmed cases, the WHO said.

"An increasing emphasis will be put on the rapid deploymentof smaller treatment facilities to ensure that capacity ismatched with demand in each area," the WHO said.

In Guinea, whose capital Conakry remains the worst-affecteddistrict, the western prefecture of Fria reported its firstEbola cases.

In Liberia, cases dropped from a peak of more than 300 newconfirmed cases per week in August and September to eight newconfirmed cases and 40 probable cases in the five days to Jan.2, it said.

Ismail Ould Cheikh Ahmed, the newly appointed head of theUnited Nations Ebola response mission known as UNMEER, warnedhowever against declaring a premature victory against thedisease during a visit to Liberia on Wednesday.

"It is only at this moment of optimism and relative successthat sometimes we are worried of a sense of complacency," hetold journalists.

Travelling with Ould Cheikh Ahmed, Bruce Aylward, the headof Ebola response at the WHO, echoed his concerns.

"There is still Ebola in Liberia and people are not actingthat way," he said. "There should be a ferocious attention todriving that number to zero and that concerns us a great deal."

On Thursday, the WHO will host a meeting of representativesfrom major drug makers, health authorities in affected countriesand national regulatory agencies to assess clinical trials ofexperimental vaccines against Ebola. GlaxoSmithKline,Merck, NewLink Genetics and Johnson & Johnson are testing experimental vaccines. (Editing by Angus MacSwan, Joe Bavier and James Dalgleish)

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.